Ventyx Biosciences (VTYX) investor relations material

Study design and objectives

• Phase II, double-blind, placebo-controlled trial in adults with obesity (BMI 30–42) and cardiovascular risk factors, randomized to VTX3232, placebo, semaglutide, or combination arms.

• 175 participants were randomized; baseline characteristics were balanced across groups, and 87% completed treatment.

• Primary endpoint was safety and tolerability; secondary and exploratory endpoints included changes in hsCRP, IL-6, liver fat, and inflammation.

Efficacy and biomarker results

• VTX3232 led to rapid, sustained ~80% reduction in hsCRP within one week, maintained over 12 weeks, with most participants achieving hsCRP <2 mg/L.

• Statistically significant reductions in IL-6, Lipoprotein(a), fibrinogen, ESR, and liver inflammation were observed, with additive anti-inflammatory effects when combined with semaglutide.

• No effect on weight loss was seen, either as monotherapy or with semaglutide.

• Significant reduction in liver inflammation, independent of steatosis, measured by CT1-corrected MRI, with additive benefit in combination therapy.

Safety and tolerability

• VTX3232 was well tolerated, with adverse event rates similar to placebo in all arms; most adverse events were mild or moderate.

• No serious or opportunistic infections were reported; one SAE (major depressive disorder) was unrelated to study drug, and neutropenia resolved after discontinuation.

• No clinically meaningful changes in lipid parameters were observed.

• TEAEs and discontinuations were balanced across groups.